Literature DB >> 26058662

Immediate and Persistent Effects of Salvinorin A on the Kappa Opioid Receptor in Rodents, Monitored In Vivo with PET.

Michael S Placzek1,2, Genevieve C Van de Bittner1, Hsiao-Ying Wey1, Scott E Lukas2, Jacob M Hooker1.   

Abstract

Monitoring changes in opioid receptor binding with positron emission tomography (PET) could lead to a better understanding of tolerance and addiction because altered opioid receptor dynamics following agonist exposure has been linked to tolerance mechanisms. We have studied changes in kappa opioid receptor (KOR) binding availability in vivo with PET following kappa opioid agonist administration. Male Sprague-Dawley rats (n=31) were anesthetized and treated with the (KOR) agonist salvinorin A (0.01-1.8 mg/kg, i.v.) before administration of the KOR selective radiotracer [(11)C]GR103545. When salvinorin A was administered 1 min prior to injection of the radiotracer, [(11)C]GR103545 binding potential (BPND) was decreased in a dose-dependent manner, indicating receptor binding competition. In addition, the unique pharmacokinetics of salvinorin A (half-life ~8 min in non-human primates) allowed us to study the residual impact on KOR after the drug had eliminated from the brain. Salvinorin A was administered up to 5 h prior to [(11)C]GR103545, and the changes in BPND were compared with baseline, 2.5 h, 1 h, and 1 min pretreatment times. At lower doses (0.18 mg/kg and 0.32 mg/kg) we observed no prolonged effect on KOR binding but at 0.60 mg/kg salvinorin A induced a sustained decrease in KOR binding (BPND decreased by 40-49%) which persisted up to 2.5 h post administration, long after salvinorin A had been eliminated from the brain. These data point towards an agonist-induced adaptive response by KOR, the dynamics of which have not been previously studied in vivo with PET.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26058662      PMCID: PMC4864638          DOI: 10.1038/npp.2015.159

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  53 in total

1.  Discovery of aminobenzyloxyarylamides as κ opioid receptor selective antagonists: application to preclinical development of a κ opioid receptor antagonist receptor occupancy tracer.

Authors:  Charles H Mitch; Steven J Quimby; Nuria Diaz; Concepcion Pedregal; Marta G de la Torre; Alma Jimenez; Qing Shi; Emily J Canada; Steven D Kahl; Michael A Statnick; David L McKinzie; Dana R Benesh; Karen S Rash; Vanessa N Barth
Journal:  J Med Chem       Date:  2011-10-26       Impact factor: 7.446

2.  Repeated exposure to the κ-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity.

Authors:  David N Potter; Diane Damez-Werno; William A Carlezon; Bruce M Cohen; Elena H Chartoff
Journal:  Biol Psychiatry       Date:  2011-07-14       Impact factor: 13.382

3.  Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen.

Authors:  Zeynep S Teksin; Insong J Lee; Noble N Nemieboka; Ahmed A Othman; Vijay V Upreti; Hazem E Hassan; Shariq S Syed; Thomas E Prisinzano; Natalie D Eddington
Journal:  Eur J Pharm Biopharm       Date:  2009-06       Impact factor: 5.571

Review 4.  G protein-coupled receptor (GPCR) trafficking in the central nervous system: relevance for drugs of abuse.

Authors:  B L Roth; D L Willins; W K Kroeze
Journal:  Drug Alcohol Depend       Date:  1998 Jun-Jul       Impact factor: 4.492

5.  Salvinorin A and derivatives: protection from metabolism does not prolong short-term, whole-brain residence.

Authors:  Jacob M Hooker; Thomas A Munro; Cécile Béguin; David Alexoff; Colleen Shea; Youwen Xu; Bruce M Cohen
Journal:  Neuropharmacology       Date:  2009-07-08       Impact factor: 5.250

Review 6.  Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.

Authors:  Christopher W Cunningham; Richard B Rothman; Thomas E Prisinzano
Journal:  Pharmacol Rev       Date:  2011-03-28       Impact factor: 25.468

7.  [11C]GR103545: novel one-pot radiosynthesis with high specific activity.

Authors:  Nabeel B Nabulsi; Ming-Qiang Zheng; Jim Ropchan; David Labaree; Yu-Shin Ding; Laura Blumberg; Yiyun Huang
Journal:  Nucl Med Biol       Date:  2010-12-03       Impact factor: 2.408

8.  Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum.

Authors:  Matthew W Johnson; Katherine A MacLean; Chad J Reissig; Thomas E Prisinzano; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2010-12-04       Impact factor: 4.492

9.  Evaluation of the kappa-opioid receptor-selective tracer [(11)C]GR103545 in awake rhesus macaques.

Authors:  Bent W Schoultz; Trine Hjornevik; Frode Willoch; János Marton; Akihiro Noda; Yoshihiro Murakami; Sosuke Miyoshi; Shintaro Nishimura; Erik Arstad; Alexander Drzezga; Ichiro Matsunari; Gjermund Henriksen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-16       Impact factor: 9.236

10.  Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects.

Authors:  Katherine A MacLean; Matthew W Johnson; Chad J Reissig; Thomas E Prisinzano; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2012-11-08       Impact factor: 4.530

View more
  7 in total

Review 1.  PET Neurochemical Imaging Modes.

Authors:  Michael S Placzek; Wenjun Zhao; Hsiao-Ying Wey; Thomas M Morin; Jacob M Hooker
Journal:  Semin Nucl Med       Date:  2016-01       Impact factor: 4.446

2.  Kappa opioid receptor binding in major depression: A pilot study.

Authors:  Jeffrey M Miller; Francesca Zanderigo; Priya D Purushothaman; Christine DeLorenzo; Harry Rubin-Falcone; R Todd Ogden; John Keilp; Maria A Oquendo; Nabeel Nabulsi; Yiyun H Huang; Ramin V Parsey; Richard E Carson; J John Mann
Journal:  Synapse       Date:  2018-07-17       Impact factor: 2.562

Review 3.  Is There a Role for GPCR Agonist Radiotracers in PET Neuroimaging?

Authors:  Matthieu Colom; Benjamin Vidal; Luc Zimmer
Journal:  Front Mol Neurosci       Date:  2019-10-18       Impact factor: 5.639

Review 4.  Role of Nuclear Imaging to Understand the Neural Substrates of Brain Disorders in Laboratory Animals: Current Status and Future Prospects.

Authors:  Annunziata D'Elia; Sara Schiavi; Andrea Soluri; Roberto Massari; Alessandro Soluri; Viviana Trezza
Journal:  Front Behav Neurosci       Date:  2020-12-11       Impact factor: 3.558

5.  Salvinorin A Does Not Affect Seizure Threshold in Mice.

Authors:  Katarzyna Socała; Urszula Doboszewska; Piotr Wlaź
Journal:  Molecules       Date:  2020-03-07       Impact factor: 4.411

Review 6.  Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders.

Authors:  Jamie A Burns; Danielle S Kroll; Dana E Feldman; Christopher Kure Liu; Peter Manza; Corinde E Wiers; Nora D Volkow; Gene-Jack Wang
Journal:  Front Psychiatry       Date:  2019-09-18       Impact factor: 4.157

Review 7.  A Survey of Molecular Imaging of Opioid Receptors.

Authors:  Paul Cumming; János Marton; Tuomas O Lilius; Dag Erlend Olberg; Axel Rominger
Journal:  Molecules       Date:  2019-11-19       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.